Korea Investment Management Announces New ETF Listings in Bio Sector
Korea Investment Management announced its plans to list two new Exchange Traded Funds (ETFs) focused on the global pharmaceutical and biotechnology industries on the 19th. The first ETF, ACE Global Big Pharma, invests in 15 major global pharmaceutical companies, selecting firms with blockbuster drugs exceeding $1 billion in annual sales. The second, ACE Eli Lilly Value Chain ETF, focuses on Eli Lilly and 14 associated companies, reflecting a trend of specialized value chain operations in the pharmaceutical industry.
Korea Investment Management aims to capture the ongoing growth potential of the global pharmaceutical market, projected to expand from $1,557 billion in 2023 to $1,917 billion by 2027. The company plans to adopt a strategic investment approach by selecting companies with high expected sales growth. This presents an attractive investment opportunity for investors looking to tap into the potential of the global pharma-bio industry.
Furthermore, the ACE Eli Lilly Value Chain ETF offers investors an in-depth approach to the healthcare sector through a collaborative development strategy centered around Eli Lilly and its partnership network. Both ETFs operate on a performance-based dividend model, with potential risks of capital loss depending on the management outcomes.
Related News
Hanwha Investment & Securities Lists Two New Bio Investment ACE ETFs - Market EconomyHanwha Investment & Securities announced on the 18th that it will list two new exchange-traded funds (ETFs) investing in bio stocks on the 19th. The products to be listed are ▲ACE Global Big Pharma and ▲ACE Eli Lilly Value Chain. The ACE Global Big Pharma ETF incorporates 15 leading large pharmaceutical companies (big pharma) in the market. Big Pharma companies are characterized by excellent capital based on drugs with annual sales exceeding $1 billion (approx. KRW 1.3932 trillion) and high economic moats. This ETF plans to selectively invest in stocks that are among the top in terms of expected revenue growth over the next three years.
"Invest in Promising Bio Companies with ETFs"...Korea Investment Management Lists Two New Bio Sector ACE ETFs - Metro Newspaper - Informative Content for Middle Class and Ordinary CitizensKorea Investment Trust Management will list two new Exchange-Traded Funds (ETFs) investing in bio sectors on the 19th. According to Korea Investment Trust Management on the 18th, the 'ACE Global Big Pharma ETF' is a product that includes 15 representative large pharmaceutical companies (big pharma) in the global market. Big pharma companies are those with annual sales of $1 billion.
Hanwha Investment & Securities Lists Two New ACE ETFs Investing in Bio Stocks - Maeil EconomyKorea Investment Management announced on the 18th that it will list two new exchange-traded funds (ETFs) on the 19th, which invest in bio stocks: 'ACE Global Big Pharma ETF' and 'ACE Eli Lilly Value Chain'. The ACE Global Big Pharma ETF is a product that includes 15 representative large pharmaceutical companies (Big Pharma) from the global market. Big Pharma companies are based on blockbuster drugs generating annual sales exceeding $1 billion.
Hanwha Investment & Securities launches first Bio ETF..."Focus on Big Pharma, Lilly"Hanwha Investment & Securities launches first Bio ETF...Focus on Big Pharma, Lilly, Hanwha Investment & Securities to newly list two Bio ETFs on the 19th
Korea Investment Management's New Listing of Two ACE ETFs Focused on Biotech InvestmentsKorea Investment Management announced on the 18th that it would be listing two new ETFs (exchange-traded funds) focused on biotech on the 19th. The two products are the 'ACE Global Big Pharma' and 'ACE Lilly Value Chain' ETFs. The 'ACE Global Big Pharma' ETF is designed to include 15 representative large pharmaceutical companies in the global market. Big pharma companies are those that have blockbuster drugs with annual sales exceeding $1 billion...
'Investment in Big Pharma and Eli Lilly Value Chain'…Korea Investment Management, Newly Lists 2 Bio ETFs - DailianKorea Investment Trust Management announced on the 18th that it will newly list two ETFs investing in bio stocks on the 19th. The products being listed are the ACE Global Big Pharma ETF and the ACE Eli Lilly Value Chain ETF. The ACE Global Big Pharma ETF incorporates 15 major pharmaceutical companies (Big Pharma) in the global market. Big Pharma companies are blockbuster companies with annual sales exceeding $1 billion.
“Focus on Big Pharma and Eli Lilly Investments”... Hanwha Investment launches two new Bio ETFs - EtodayHanwha Investment Trust Management announced on the 18th that it will list two new ETFs focusing on bio stocks, effective from the 19th. The two products are 'ACE Global Big Pharma ETF' and 'A
Korea Investment Management launches 'Global Big Pharma' and 'Eli Lilly Value Chain' ETFs - EdailyKorea Investment Trust Management announced on the 18th that it will newly list two exchange-traded funds (ETFs), 'ACE Global Big Pharma' and 'ACE Eli Lilly Value Chain', which invest in bio stocks on the 19th. According to Korea Investment Trust Management, the ACE Global Big Pharma ETF is a representative large pharmaceutical company in the global market...